Prostate cancer is the most common non skin cancer in American men, with more than 300,000 new cases expected in 2026. For decades, the standard treatments for localized prostate cancer were radical prostatectomy (surgical removal of the entire prostate) or radiation therapy. While effective, these whole gland treatments often cause significant side effects: urinary incontinence, erectile dysfunction, and bowel problems. Many men with low or intermediate risk cancer began to wonder whether destroying the entire prostate was necessary when only one small area contained cancer.
Focal therapy offers an answer. Instead of treating the whole gland, focal therapy targets only the visible cancerous lesion (or lesions) while leaving the rest of the prostate and its surrounding nerves intact. The goal is to destroy the clinically significant cancer while preserving urinary and erectile function. Three main technologies are used today: high intensity focused ultrasound (HIFU), cryoablation (freezing), and irreversible electroporation (IRE). Each has unique advantages, and together they represent a major shift toward personalized, precision oncology.
At Adult & Pediatric Urology , we follow these advances closely. Understanding all treatment options, including focal therapy, empowers patients to make informed decisions that align with their values and quality of life goals.
What Is Focal Therapy and Who Is a Candidate?
Focal therapy treats only the area of the prostate that contains the index (most significant) cancer lesion. Before treatment, a multiparametric MRI (mpMRI) identifies suspicious areas, and a targeted biopsy confirms the presence and grade of cancer. A typical candidate has:
- Unilateral (one side of the prostate) or well localized cancer
- Grade Group 1 or 2 (Gleason 3+3 or 3+4)
- PSA less than 15 ng/mL
- No evidence of cancer outside the prostate on MRI
- Prostate volume suitable for the chosen technology
Focal therapy is not recommended for men with high risk cancer (Grade Group 4 5), bilateral diffuse disease, or evidence of extracapsular extension or seminal vesicle invasion. However, for appropriately selected patients, focal therapy offers a middle ground between active surveillance (watching and waiting) and radical whole gland treatment.
The concept of treating only the cancer focus is not new, but advances in imaging and ablation technology have made it practical. The article Comparing Erectile Dysfunction Medications: Viagra, Cialis, Levitra, and Stendra is relevant because preserving erectile function is a major advantage of focal therapy over radical treatments.
High Intensity Focused Ultrasound (HIFU)
HIFU uses focused ultrasound waves to heat prostate tissue to 80 95°C, causing coagulative necrosis. The procedure is performed transrectally under general or spinal anesthesia. A probe inserted into the rectum emits ultrasound energy that converges on the targeted lesion, ablating it within a few seconds while sparing surrounding structures.
Efficacy Data
A large systematic review and meta analysis published in 2024 2025 evaluated outcomes of HIFU, cryoablation, and IRE. For HIFU, the pooled rate of being free from clinically significant cancer on follow up biopsy (the primary oncologic endpoint) was approximately 85 90% at 12 24 months. The rate of salvage therapy (prostatectomy or radiation for recurrence) was around 15 20% at 5 years – meaning most men avoided whole gland treatment.
Functional Outcomes
- Urinary continence: 95 98% of men retained normal continence (no pads or security pad).
- Erectile function: 70 80% of men with normal erections before treatment were able to have intercourse without medication at 12 months. This rate is significantly higher than after radical prostatectomy (30 50%) or radiation (40 60%).
- No bowel complications: Because the probe is in the rectum, there is a small risk of rectal injury (<1%), but unlike external beam radiation, HIFU does not cause chronic radiation proctitis.
Men who are concerned about Erectile Dysfunction Causes, Symptoms, Diagnosis & Treatment may find that focal therapy offers a much lower risk of ED than traditional treatments.
Cryoablation (Cryotherapy)
Cryoablation destroys prostate tissue by freezing it to very low temperatures ( 40°C or below). Thin needles (cryoprobes) are inserted through the perineal skin under ultrasound guidance. Argon gas creates an ice ball that expands to cover the target lesion. Two freeze thaw cycles are typically performed to ensure cell death.
Efficacy Data
In the same systematic review, cryoablation had similar oncologic outcomes to HIFU. The rate of freedom from clinically significant cancer on repeat biopsy ranged from 80 88% at 12 24 months. Long term data (5 10 years) is more mature for cryoablation than for HIFU or IRE, showing 5 year biochemical recurrence free survival of 70 75% for low and intermediate risk patients treated focally.
Functional Outcomes
- Urinary continence: Also 95% or higher.
- Erectile function: Slightly lower than HIFU, around 60 70% preservation, because the freezing can sometimes affect the neurovascular bundles near the capsule.
- Urethral sloughing: A unique risk of cryoablation is sloughing of dead tissue into the urethra, causing temporary obstruction or irritative symptoms (5 10%). This usually resolves with a short catheter course.
Cryoablation is particularly useful for patients who cannot have MRI (e.g., due to pacemaker) because it can be performed under ultrasound guidance alone, though MRI cryoablation fusion is preferred.
Irreversible Electroporation (IRE)
IRE is the newest of the three technologies. It uses short, high voltage electrical pulses to create nanoscale pores in the cell membrane, leading to cell death without thermal damage. Unlike HIFU or cryoablation, IRE does not heat or freeze tissue. This means it spares the extracellular matrix, blood vessels, and nerves – structures that are vulnerable to extreme temperatures. The procedure is performed under general anesthesia with muscle paralysis, because the electrical pulses can cause muscle contractions.
Efficacy Data
Early studies show that IRE achieves complete ablation of the target lesion in 75 85% of men on follow up biopsy. Because IRE is newer, long term data are less mature. However, a 2025 multicenter study reported 2 year disease free survival of 85% for low risk and 78% for intermediate risk patients.
Functional Outcomes
- Urinary continence: Over 98% remain pad free.
- Erectile function: The highest preservation rate of all three – 85 90% of men maintain baseline erectile function. This is because the neurovascular bundles are largely spared from thermal injury.
- No urethral or rectal injury: The non thermal mechanism makes IRE exceptionally safe for peri urethral and peri rectal tissues.
For men who prioritize sexual function above all else, IRE may be the best choice among focal therapies. However, it requires specialized equipment and expertise, and it is not yet as widely available as HIFU or cryoablation.
The article Erectile Dysfunction – Personalized Medical Treatment at Our Urology often becomes relevant after any prostate cancer treatment. With focal therapy, many men may not need ED treatment at all.
Oncologic and Functional Outcomes: Systematic Review 2024 2025
The comprehensive systematic review and meta analysis published in 2024 – 2025 summarized outcomes across HIFU, cryoablation, and IRE:
| Outcome | HIFU | Cryoablation | IRE |
|---|---|---|---|
| Freedom from significant cancer on biopsy (12-24 months) | 85-90% | 80-88% | 80-85% |
| Continence preservation (pad free) | 95-98% | 95-98% | 98% |
| Erectile function preservation (baseline to 12 months) | 70-80% | 60-70% | 85-90% |
| Salvage therapy rate (5 years) | 15-20% | 15-25% | <15% (preliminary) |
| Major complications | <2% | 2-5% | <1% |
The authors concluded that focal therapy, regardless of energy source, achieves good short and medium term oncologic control with excellent preservation of urinary and erectile function in carefully selected patients. The choice of technology should be individualized based on lesion location, prostate anatomy, patient preference, and local expertise.
Focal Therapy vs. Radical Prostatectomy vs. Radiation
The table below compares focal therapy with the two traditional whole gland treatments.
| Aspect | Focal Therapy | Radical Prostatectomy | Radiation (IMRT or Brachytherapy) |
|---|---|---|---|
| Hospital stay | Outpatient or 1 night | 1-2 nights | None (outpatient) |
| Catheter | 2-7 days | 7-14 days | None or few days |
| Urinary incontinence (long term) | 2-5% | 15-25% | 5-10% |
| Erectile dysfunction (long term) | 20-30% | 50-70% | 40-60% |
| Bowel complications | Rare | None | 10-20% (chronic proctitis) |
| Ability to retreat | Yes | No | Limited |
| Oncologic control (10 year, low risk) | 85-90% (focal) | 95-98% | 95-98% |
For low and intermediate risk prostate cancer, the oncologic difference between focal therapy and whole gland treatments is small, but the functional benefit of focal therapy is large. Many men are willing to accept a slightly higher risk of needing a second treatment (salvage therapy) in exchange for preserving urinary and erectile function.
Men who are considering their options should read Men’s Urology Care – How Our Clinic Supports Men’s Health for a broader perspective on prostate health.
The Importance of Proper Patient Selection and Follow Up
Focal therapy is not for everyone. The most critical factor for success is accurate identification of the target lesion. This requires high quality mpMRI and systematic plus targeted biopsy (preferably MRI ultrasound fusion). After treatment, patients undergo regular PSA monitoring and repeat MRI and biopsy at 6 12 months to confirm complete ablation.
Men with a family history of prostate cancer or those who have had elevated PSA levels should start with Prostate Cancer – PSA Screening and Diagnosis and then discuss focal therapy with their urologist if cancer is found.
Frequently Asked Questions
Is focal therapy as effective as removing the whole prostate?
For carefully selected men with low or intermediate risk cancer, focal therapy offers similar cancer control rates (85 90% free of significant cancer on biopsy) with much lower side effects. The trade off is a 15 20% chance of needing a second treatment later.
Will I need additional treatment after focal therapy?
Not necessarily. The majority of men do not need further treatment. However, about 15 20% may develop a new cancer in another area of the prostate or have residual disease, and then can undergo repeat focal therapy or whole gland treatment.
Which focal therapy technology is best?
There is no single best technology. HIFU is most widely available. Cryoablation has longer follow up data. IRE has the best erectile function preservation and lowest risk of collateral damage. The choice depends on your lesion location and the expertise at your center.
Does insurance cover focal therapy?
Coverage varies. Medicare covers cryoablation and HIFU for prostate cancer under specific circumstances. IRE is often considered investigational by some insurers. Always check with your insurance provider before proceeding.
How do I know if I am a candidate for focal therapy?
You are likely a candidate if you have a single, visible lesion on MRI, Grade Group 1 or 2 cancer on targeted biopsy, PSA <15, and no evidence of cancer spread. A discussion with a urologist experienced in focal therapy is essential.
Medical Disclaimer
The information provided in this article is for educational purposes only and does not substitute professional medical advice. Focal therapy is an established treatment for select patients with localized prostate cancer, but it is not appropriate for everyone. Always consult a licensed healthcare provider to discuss your individual diagnosis, treatment options, and potential risks and benefits.
Author And Reviewer
Author – John K. Matsuura, M.D.
Reviewer – Gregory S. Parries, M.D., PhD.
Last updated: May 22, 2026